Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo aims to tame Graft-Versus-Host disease in older blood cancer patients

NCT ID NCT07228624

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding the drug ruxolitinib to standard care can prevent graft-versus-host disease (GVHD) in older patients with myelofibrosis or MDS/MPN overlap syndromes who receive a donor stem cell transplant. About 50 participants will get ruxolitinib before, during, and after the transplant, along with chemotherapy and standard GVHD prevention. The main goal is to see if this approach lowers the rate of moderate-to-severe GVHD compared to historical results.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ruxolitinib (a JAK inhibitor drug) given before, during, and after a donor stem cell transplant
What this could lead to
If it works, this could reduce the risk of graft-versus-host disease and improve outcomes for older patients with myelofibrosis or related blood cancers.
What could go wrong
This is a small, early-phase trial (50 participants) with no guarantee of success. Adding ruxolitinib may increase side effects or fail to prevent GVHD better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic/myeloproliferative disease myelodysplastic/myeloproliferative neoplasm myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM PRIMARY MYELOFIBROSIS SECONDARY MYELOFIBROSIS

Contacts and locations

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.